AIM: To evaluate the clinical efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment.

METHODS: A total of 66 patients(66 eyes)from May, 2012 to April, 2013 were randomized into 2 groups. The treatment group(34 eyes)was received an intralesional injection of bevacizumab 1.25mg(100mg/4mL)each time, once a month, a total of three times. The control group(32 eyes)was received a combination of artificial tears and non-steroidal anti-inflammatory eye drops.

RESULTS: After 6mo follow-up, it was showed that there was a statistically significant reduction of injection and the elevation of pterygium was compared with the baseline in both groups(P<0.05). There was no significant difference of vision, intraocular pressure and percentage of corneal pterygium compared with the baseline in both groups(P>0.05).

CONCLUSION:Intralesional bevacizumab can control primary pterygium effectively for at least 6mo with no serious ocular or systemic adverse effects.